Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 4/20 | 0.56 |
| ▸ | METAP2 | P50579 | 3/20 | 0.56 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.35 |
| ▸ | FLT1 | P17948 | 1/20 | 0.35 |
| ▸ | PDE5A | O76074 | 3/20 | 0.35 |
| ▸ | AURKA | O14965 | 5/20 | 0.34 |
| ▸ | WNT1 | P04628 | 1/20 | 0.32 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.32 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.32 |
| ▸ | HPSE | Q9Y251 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL467132 | 0.78 | METAP2 (0.57) | METAP1METAP2NPY5RFGFR1FLT1 | |
| SCHEMBL6385063 | 0.75 | METAP2 (0.60) | METAP1METAP2NPY5RWNT1 | |
| SCHEMBL4875487 | 0.73 | METAP1 (0.67) | METAP1METAP2NPY5RFGFR1FLT1 | |
| SCHEMBL8777040 | 0.73 | METAP2 (0.51) | METAP1METAP2NPY5RPTGDR2 | |
| SCHEMBL680854 | 0.72 | METAP2 (0.65) | METAP1METAP2NPY5RAURKAPTGDR2 | |
| SCHEMBL4924097 | 0.72 | METAP2 (1.00) | METAP1METAP2AURKA | |
| Hydrochloric Acid SCHEMBL4456676 | 0.71 | METAP2 (0.63) | METAP1METAP2NPY5RAURKAPTGDR2 | |
| SCHEMBL7035590 | 0.71 | METAP1 (0.72) | METAP1METAP2NPY5RFGFR1FLT1 | |
| SCHEMBL82498 | 0.71 | NPC1 (0.58) | METAP1METAP2AURKA | |
| SCHEMBL369485 | 0.70 | METAP2 (0.61) | METAP1METAP2NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1021429-A1 | ARYL FURAN DERIVATIVES AS PDE IV INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2000-07-26 | — | — | EP | claimed |
| WO-1999018095-A1 | ARYL FURAN DERIVATIVES AS PDE IV INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 1999-04-15 | — | — | WO | claimed |
| EP-2402341-B1 | Purinyl derivatives and their use as potassium channel modulators | SANIONA AS (DK) | 2017-10-25 | — | — | EP | disclosed |
| US-9340544-B2 | Purinyl derivatives and their use as potassium channel modulators | ATAXION, INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20130109704-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2013-05-02 | — | — | US | disclosed |
| US-8362024-B2 | Purinyl derivatives and their use as potassium channel modulators | NEUROSEARCH A/S (DK) | 2013-01-29 | — | — | US | disclosed |
| US-20120004246-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2012-01-05 | — | — | US | disclosed |
| EP-2402341-A2 | Purinyl derivatives and their use as potassium channel modulators | NeuroSearch A/S (DK) | 2012-01-04 | — | — | EP | disclosed |
| US-20100152210-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEURO SEARCH A/S/ (DK) | 2010-06-17 | — | — | US | disclosed |
| US-20100130516-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-05-27 | — | — | US | disclosed |
| US-20100120797-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2010-05-13 | — | — | US | disclosed |
| EP-2142547-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NeuroSearch A/S (DK) | 2010-01-13 | — | — | EP | disclosed |
| EP-2132208-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NeuroSearch AS (DK) | 2009-12-16 | — | — | EP | disclosed |
| WO-2008116909-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116910-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116912-A2 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116914-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008116911-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | NEUROSEARCH A/S (DK) | 2008-10-02 | — | — | WO | disclosed |
| EP-1021429-A1 | ARYL FURAN DERIVATIVES AS PDE IV INHIBITORS | MERCK FROSST CANADA INC. (CA) | 2000-07-26 | — | — | EP | disclosed |
| WO-1999018095-A1 | ARYL FURAN DERIVATIVES AS PDE IV INHIBITORS | MERCK FROSST CANADA & CO. (CA) | 1999-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004246-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNJ5, KCNJ3 | METAP1 4100/4885METAP2 3728/4885NPY5R 2098/4885 |
| US-20130109704-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNJ5, KCNJ3 | METAP1 4100/4885METAP2 3728/4885NPY5R 2098/4885 |
| US-20100152210-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNJ5, KCNJ3 | METAP1 4100/4885METAP2 3728/4885NPY5R 2098/4885 |
| US-20100120797-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNJ5, KCNJ3 | METAP1 4100/4885METAP2 3728/4885NPY5R 2098/4885 |
| US-20100130516-A1 | PURINYL DERIVATIVES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS | KCNJ2, KCNJ5, KCNJ3 | METAP1 4100/4885METAP2 3728/4885NPY5R 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.